Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Open-Label Study of PTC923 (Sepiapterin) in Phenylketonuria
2021-000497-28Phase 3Active
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sepiapterin in phenylketonuria (PKU), sponsored by PTC Therapeutics, Inc. Primary endpoint: Long-term safety of PTC923. Started Dec 2021; status: active.
02
Drugs
sepiapterin
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on 2021-000497-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000497-28.